{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:06:23Z","timestamp":1769850383624,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis 1 (NF1) is an inherited, autosomal-dominant, tumor predisposition syndrome with a birth incidence as high as 1:2000. A patient with NF1 is four to five times more likely to develop a malignancy as compared to the general population. The number of epidemiologic studies on lymphoproliferative malignancies in patients with NF1 is limited. The aim of this study was to determine the incidence rate of lymphoproliferative malignancies (lymphoma and  leukemia) in NF1 patients followed in our referral center for neurofibromatoses. We used the Informatics for Integrated Biology and the Bedside (i2b2) platform to extract information from the hospital\u2019s electronic health records. We performed a keyword search on clinical notes generated between Jan\/01\/2014 and May\/11\/2020 for patients aged 18\u00a0years or older. A total of 1507 patients with confirmed NF1 patients aged 18\u00a0years and above were identified (mean age 39.2\u00a0years; 57% women). The total number of person-years in follow-up was 57,736 (men, 24,327\u00a0years; women, 33,409\u00a0years). Mean length of follow-up was 38.3\u00a0years (median, 36\u00a0years). A total of 13 patients had a medical history of either lymphoma or leukemia, yielding an overall incidence rate of 22.5 per 100,000 (0.000225, 95% confidence interval (CI) 0.000223\u20130.000227). This incidence is similar to that of the general population in France (standardized incidence ratio 1.07, 95% CI 0.60\u20131.79). Four patients had a medical history leukemia and 9 patients had a medical history of lymphoma of which 7 had non-Hodgkin lymphoma, and 2 had Hodgkin lymphoma. Our results show that adults with NF1 do not have an increased tendency to develop lymphoproliferative malignancies, in contrast to the general increased risk of malignancy. While our results are consistent with the recent population-based study in Finland, they are in contrast with the larger population-based study in England whereby NF1 individuals were found to be 3 times more likely to develop both non-Hodgkin lymphoma and lymphocytic leukemia. Large-scale epidemiological studies based on nationwide data sets are thus needed to confirm our findings.<\/jats:p>","DOI":"10.1186\/s13023-021-01856-8","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T18:15:28Z","timestamp":1621448128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lymphoproliferative malignancies in patients with neurofibromatosis 1"],"prefix":"10.1186","volume":"16","author":[{"given":"Christina","family":"Bergqvist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Hemery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Jannic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah","family":"Ferkal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-457X","authenticated-orcid":false,"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"1856_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/jid.2014.465","volume":"135","author":"E Uusitalo","year":"2015","unstructured":"Uusitalo E, Leppavirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T, Poyhonen M, Peltonen J, Peltonen S. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol. 2015;135:904\u20136. https:\/\/doi.org\/10.1038\/jid.2014.465.","journal-title":"J Invest Dermatol"},{"key":"1856_CR2","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Prim. 2017;3:17004. https:\/\/doi.org\/10.1038\/nrdp.2017.4.","journal-title":"Nat Rev Dis Prim"},{"key":"1856_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","volume":"62","author":"GF Xu","year":"1990","unstructured":"Xu GF, O\u2019Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599\u2013608. https:\/\/doi.org\/10.1016\/0092-8674(90)90024-9.","journal-title":"Cell"},{"key":"1856_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.2134734","volume":"249","author":"MR Wallace","year":"1990","unstructured":"Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181\u20136. https:\/\/doi.org\/10.1126\/science.2134734.","journal-title":"Science"},{"key":"1856_CR5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/320121.","volume":"68","author":"SA Rasmussen","year":"2001","unstructured":"Rasmussen SA, Yang Q. Friedman JM (2001) Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet. 2001;68:1110\u20138. https:\/\/doi.org\/10.1086\/320121.","journal-title":"Am J Hum Genet"},{"key":"1856_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","volume":"19","author":"DG Evans","year":"2011","unstructured":"Evans DG, O\u2019Hara C, Wilding A, Ingham SL, Howard E, Dawson J, Moran A, Scott-Kitching V, Holt F, Huson SM. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet. 2011;19:1187\u201391. https:\/\/doi.org\/10.1038\/ejhg.2011.113.","journal-title":"Eur J Hum Genet"},{"key":"1856_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/bjc.2012.535","volume":"108","author":"OO Seminog","year":"2013","unstructured":"Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer. 2013;108:193\u20138. https:\/\/doi.org\/10.1038\/bjc.2012.535.","journal-title":"Br J Cancer"},{"key":"1856_CR8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionpaa RA, Poyhonen M, Leppavirta J, Yla-Outinen H, Riccardi VM, Pukkala E, Pitkaniemi J, Peltonen S, Peltonen J. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34:1978\u201386. https:\/\/doi.org\/10.1200\/JCO.2015.65.3576.","journal-title":"J Clin Oncol"},{"key":"1856_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1752-1947-6-8","volume":"6","author":"S Lueangarun","year":"2012","unstructured":"Lueangarun S, Auewarakul CU. Diffuse large B cell lymphoma presenting as Horner\u2019s syndrome in a patient diagnosed with neurofibromatosis type 1: a case report and review of the literature. J Med Case Rep. 2012;6:8. https:\/\/doi.org\/10.1186\/1752-1947-6-8.","journal-title":"J Med Case Rep"},{"key":"1856_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","volume":"45","author":"NI Neurofibromatosis","year":"1988","unstructured":"Neurofibromatosis NI. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575\u20138.","journal-title":"Arch Neurol"},{"key":"1856_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bulcan.2018.11.016","volume":"106","author":"A Cowppli-Bony","year":"2019","unstructured":"Cowppli-Bony A, Colonna M, Ligier K, Jooste V, Defossez G, Monnereau A, le Reseau F. Reseau des registres de cancer F: Descriptive epidemiology of cancer in metropolitan France: incidence, survival and prevalence. Bull Cancer. 2019;106:617\u201334. https:\/\/doi.org\/10.1016\/j.bulcan.2018.11.016.","journal-title":"Bull Cancer"},{"key":"1856_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s0022-3476(78)80362-x","volume":"92","author":"JL Bader","year":"1978","unstructured":"Bader JL, Miller RW. Neurofibromatosis and childhood leukemia. J Pediatr. 1978;92:925\u20139. https:\/\/doi.org\/10.1016\/s0022-3476(78)80362-x.","journal-title":"J Pediatr"},{"key":"1856_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/bjc.1991.216","volume":"63","author":"SA Narod","year":"1991","unstructured":"Narod SA, Stiller C, Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer. 1991;63:993\u20139. https:\/\/doi.org\/10.1038\/bjc.1991.216.","journal-title":"Br J Cancer"},{"key":"1856_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/bjc.1994.431","volume":"70","author":"CA Stiller","year":"1994","unstructured":"Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia\/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994;70:969\u201372. https:\/\/doi.org\/10.1038\/bjc.1994.431.","journal-title":"Br J Cancer"},{"key":"1856_CR15","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/ijc.32187","volume":"145","author":"S Peltonen","year":"2019","unstructured":"Peltonen S, Kallionpaa RA, Rantanen M, Uusitalo E, Lahteenmaki PM, Poyhonen M, Pitkaniemi J, Peltonen J. Pediatric malignancies in neurofibromatosis type 1: a population-based cohort study. Int J Cancer. 2019;145:2926\u201332. https:\/\/doi.org\/10.1002\/ijc.32187.","journal-title":"Int J Cancer"},{"key":"1856_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","volume":"10","author":"H Brems","year":"2009","unstructured":"Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10:508\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(09)70033-6.","journal-title":"Lancet Oncol"},{"key":"1856_CR17","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"key":"1856_CR18","doi-asserted-by":"publisher","first-page":"e38463","DOI":"10.1371\/journal.pone.0038463","volume":"7","author":"Z KalenderAtak","year":"2012","unstructured":"KalenderAtak Z, De Keersmaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D, Porcu M, Lahortiga I, Brys V, Dirks WG, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS ONE. 2012;7:e38463. https:\/\/doi.org\/10.1371\/journal.pone.0038463.","journal-title":"PLoS ONE"},{"key":"1856_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJM199403033300903","volume":"330","author":"KM Shannon","year":"1994","unstructured":"Shannon KM, O\u2019Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330:597\u2013601. https:\/\/doi.org\/10.1056\/NEJM199403033300903.","journal-title":"N Engl J Med"},{"key":"1856_CR20","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/blood.V84.10.3435.3435","volume":"84","author":"R Kalra","year":"1994","unstructured":"Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood. 1994;84:3435\u20139.","journal-title":"Blood"},{"key":"1856_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/ng0296-144","volume":"12","author":"G Bollag","year":"1996","unstructured":"Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12:144\u20138. https:\/\/doi.org\/10.1038\/ng0296-144.","journal-title":"Nat Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01856-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01856-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01856-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T18:17:31Z","timestamp":1621448251000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01856-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01856-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the national institute concerning health data (INDS) and conducted according to local standards and laws (MR003 standard and Law Informatique et liberte\u0301 number 78-1, specifying that retrospective data studies are not considered by French law as involving human subjects).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}